ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.

Mansoor N Saleh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.